Found 279 articles
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
Sosei Group Corporation announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd..
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan®) using its multi-targeted antibody therapy enhancer (MATE) platform.
11/23/2020Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look.
Value-based agreement between Prime Therapeutics and Biohaven aims to bring NURTEC™ ODT acute migraine treatment financial protection to health plans
Up to 55% of migraine patients do not have sufficient relief with currently available treatments.2 NURTEC™ ODT (rimegepant) can work quickly, returning patients to normal function in as little as one hour.
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque psoriasis
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
- National Ataxia Foundation (NAF) Drug Development Collaborative to cultivate resources that facilitate research and development of new potential treatments for Ataxia, a set of severe and debilitating neurodegenerative diseases - Biohaven Pharmaceuticals, the first industry sponsor of the Collaborative, is currently conducting a Phase 3 clinical trial of troriluzole for Spinocerebellar Ataxia (SCA)
Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE™) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced the presentation of proof-of-concept data on KPMW101, an anti-tumor therapeutic agent created with the company’s multi-targeted antibody therapy enhancer conjugation platform.
$60.0 million Series A funding completed by Asia-Pacific subsidiary, BioShin to bring NURTEC™ ODT to an estimated 80 million migraine sufferers in China
Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming third quarter 2020 earnings call and webcast, reporting financial results for the quarter ended September 30, 2020
Kleo Pharmaceuticals Announces Data Presentation on Novel Conjugation Platform at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting
Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data from its multi-targeted antibody therapy enhancer (MATE™) conjugation platform at the upcoming Society for Immunotherapy of Cancer's (SITC) 35 th Annual Meeting. The meeting is taking place in a virtual format from November 9-14, 2020. Details of the p
U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine
Acceptance marks critical milestone in Biohaven's efforts to develop NURTEC ODT as a unique dual therapy for both the preventive and acute treatment of migraine NURTEC ODT 75 mg has been shown in placebo-controlled trials to return patients to normal functioning within 60 minutes when used in the acute treatment of migraine and has also been shown to reduce monthly migraine days at the same 75 mg dose administered every other day for preventive treatment
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
Initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20
Kleo Pharmaceuticals to Present at “Bioscience Pipeline & Innovation in Connecticut in the Age of COVID” Conference
Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present today to local stakeholders at the Bioscience Pipeline & Innovation in Connecticut in the Age of COVID conference on Monday, September 21, 2020 at 2:00 p.m. ET
FDA Granted Pediatric Disease Designation for OXi-4503-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients
Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that the US Food and Drug Administration (FDA) granted our request and designate OXi4503 (combretastatin A1-diphosphate; CA1P) for treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease,” as defined in section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
- Investigational New Drug (IND) application was authorized to proceed by the US FDA for human dosing with oral zavegepant - Biohaven achieved first in human dosing with oral zavegepant to assess the safety and pharmacokinetic profile - Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation
Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple MyelomaCD38-Targeting Molecule To be Evaluated in Multiple Patient Populations
Kleo Pharmaceuticals, a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced today that its lead compound, KP1237, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in multiple myeloma. KP1237 is an antibody-redirecting molecule (ARMä) that targets CD38, a clinically validated target for multiple myeloma. “We are pleased to r
Atea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership
Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience
8/10/2020It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
- NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share - Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement - Remains on timelines for NURTEC ODT sNDA filing for prevention of migraine in the coming months; additionally, completion of troriluzole Alzheimer's Disease Phase 2/3 trial in 4Q2020, and topline resu